-
Mashup Score: 0Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors - 8 month(s) ago
AbstractBackground. Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment of ovarian cancer; however, real-world data on kidney func
Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Niraparib Maintenance Therapy Induces Antitumor Activity in Advanced Ovarian Cancer - 11 month(s) ago
The use of maintenance niraparib therapy led to clinically meaningful improvement in progression-free survival, compared with placebo, in patients with newly diagnosed, advanced ovarian cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the phase 3 PRIME study, #niraparib maintenance therapy led to additional antitumor activity in patients with newly diagnosed advanced ovarian cancer. #gyncsm #ASCO2023 https://t.co/6gxWrlyCGp
-
-
Mashup Score: 0Adapting to Second-Line Restrictions of Niraparib in Ovarian Cancer - 11 month(s) ago
The approved PARP inhibitor niraparib has been beneficial for patients with recurrent ovarian cancer, but new second-line restrictions for certain patients have led physicians to be more cautious when re-challenging these patients.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Crane discusses #niraparib for patients with recurrent ovarian cancer and highlights new second-line restrictions for certain patients. #gyncsm | @AtriumHealth https://t.co/ehhmg2Y8Fi
-
-
Mashup Score: 0Niraparib Results Encourage Somatic Tumor Profiling in Ovarian Cancer - 12 month(s) ago
Matthew Anderson, MD, PhD, discusses how the results with niraparib for patients with advanced ovarian cancer impacts the use of somatic profiling in this patient population.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Matthew Anderson, MD, PhD, discusses #niraparib as a treatment for advanced #ovariancancer. #gyncsm | @TGHCares @USFHealthMed https://t.co/yZMMYM1Kun
-
-
Mashup Score: 1
Treatment with niraparib elicited durable conditional progression-free survival rates vs placebo in patients with ovarian cancer whose tumors were homologous recombination deficient.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with ovarian cancer whose tumors were homologous recombination deficient treated with #niraparib had durable conditional PFS rates vs placebo up to 4 years post-randomization. #gyncsm #ESMOGynae23 | @myESMO https://t.co/NS0IGR3BNH
-
-
Mashup Score: 0Niraparib maintenance therapy fails to significantly extend OS in recurrent ovarian cancer - 1 year(s) ago
Niraparib did not significantly extend OS among women with recurrent ovarian cancer, according to long-term follow-up results of the ENGOT-OV16/NOVA trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. A previously presented analysis of OS, a secondary endpoint of the trial, had been limited due to missing follow-up data on survival status and
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Niraparib maintenance therapy fails to significantly extend OS in recurrent ovarian cancer. https://t.co/SXoujhROcJ #OvarianCancer #Niraparib @DanaFarber #SGOMtg #gynonc #sgo2023 @SGO_org #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0
Findings from the second interim analysis of the phase 3 MAGNITUDE study showed the positive benefit of niraparib plus abiraterone and prednisone in metastatic castration-resistant prostate cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Niraparib + abiraterone + prednisone led to prolonged survival, extended time to cytotoxic chemotherapy, and delayed progression in patients with #mCRPC and HRR gene alterations. #pcsm https://t.co/xvxryXvmod
-
-
Mashup Score: 0
Data from the second interim analysis of the phase 3 MAGNITUDE study showed that the addition of niraparib to abiraterone acetate and prednisone prolonged survival for patients with metastatic castration-resistant prostate cancer with BRCA mutations.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
An #NDA has been submitted to the #FDA seeking the approval of #niraparib in combination with #abiraterone acetate and prednisone for patients with BRCA+ #mCRPC. #pcsm https://t.co/eLZDSXleza
-
-
Mashup Score: 0Niraparib regimen improves outcomes for men with prostate cancer, HRR gene alterations - 1 year(s) ago
SAN FRANCISCO — The addition of niraparib to abiraterone acetate and prednisone improved multiple outcomes for certain men with metastatic castration-resistant prostate cancer, according to randomized phase 3 study results.A second interim analysis of the MAGNITUDE trial — presented at ASCO Genitourinary Cancers Symposium — showed the combination extended radiographic PFS for
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#GU23 Niraparib regimen improves outcomes for men with prostate cancer, HRR gene alterations. https://t.co/293wCCgeIw #Niraparib @MethodistHosp @ASCO #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0
Findings from the second interim analysis of the phase 3 MAGNITUDE study showed the positive benefit of niraparib plus abiraterone and prednisone in metastatic castration-resistant prostate cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the second interim analysis of the phase 3 MAGNITUDE study, there was a positive benefit with #niraparib plus #abiraterone and #prednisone in metastatic castration-resistant prostate cancer. #mpcrc #pcsm #GU23 | @ASCO https://t.co/Pdz2IzeaX4
-
This study in @JNCI_Now investigates the incidence of acute kidney injury (AKI) in #ovariancancer patients treated with #olaparib or #niraparib. They found 22.3% developed AKI but only 3.3% had AKI related to the #PARP inhibitor. #gyncsm Read more: https://t.co/qiRAfsMxDK https://t.co/2iYEn8jvVP